Ajinomoto Co., Inc. Overview
Ajinomoto is a Japanese food and amino-acid science group with two profit engines of very different character. The first is a branded seasonings and processed foods franchise, anchored in Japan and in five core emerging markets (Thailand, Indonesia, Vietnam, the Philippines, Brazil), which generates stable mid-teens business profit margins and most of group cash flow. The second is a Bio & Fine Chemicals portfolio built on the same fermentation and amino-acid chemistry: pharmaceutical-grade amino acids, contract drug development and manufacturing (including Forge Biologics gene therapy), and Ajinomoto Build-up Film (ABF), the dominant insulating film in high-performance semiconductor package substrates. ABF demand from AI servers has made the Healthcare and Others segment the fastest-growing contributor, lifting group business profit to a record JPY 181.2 billion in FY2025. Frozen foods remain a low-return drag. The equity now trades as a hybrid of consumer staple and semiconductor materials supplier.
What the company does
Ajinomoto manufactures and sells seasonings, processed foods, frozen foods, coffee products, amino acids, pharmaceutical contract services and electronic materials. The common technical root is amino-acid fermentation and chemistry, which the company brands as "AminoScience". Its stated purpose is to contribute to the well-being of people, society and the planet through that science. [Corporate Governance Report, 19 June 2026]
Company's own description
In its segment note the company states that its reportable segments are organised mainly by product line and comprise three: Seasonings and Foods, Frozen Foods, and Healthcare and Others. A residual "Other" category covers tie-up and service businesses. Management groups the first two as the "Food Products business" and the third as the "Bio & Fine Chemicals business". [Kessan Tanshin FY2025, segment information]
Independent characterization
Ajinomoto is best understood as three businesses under one roof.
-
A consumer franchise with emerging-market pricing power. Sauce & Seasonings and Quick Nourishment sell through local-staff-led distribution networks reaching traditional trade in Southeast Asia and Latin America. In FY2025, Japan sales in these categories grew 11% (volume down 4%, unit prices up 15%), and overseas sales grew 4% in local currency (volume and price each up 2%). [FY2025 results presentation, 7 May 2026]
-
A structurally challenged frozen foods business. Scale is meaningful (JPY 290 billion) but business profit was only JPY 8.5 billion in FY2025, a margin under 3%.
-
A specialty materials and life-science business with exceptional economics in one product. Functional Materials, mainly ABF, carries a business profit margin that management puts above 50%. [FY2025 results presentation]
Revenue model
| Revenue type | Where it arises | Comment |
|---|---|---|
| Product sales (consumer) | Seasonings, soups, coffee, frozen foods, supplements | Dominant share of revenue; sold through retailers, wholesalers and traditional trade |
| Product sales (B2B) | Solution & Ingredients, amino acids, ABF, functional materials | Sold to food processors, pharma companies, substrate makers |
| Services | Bio-Pharma Services (CDMO) | Fee-for-service development and manufacturing |
| Licensing | AJICAP site-specific conjugation technology; AJIPHASE oligonucleotide synthesis | Technology licences alongside contract services; amounts not publicly disclosed |
| Subscription | Not a material revenue model | — |
The exact product/service/licensing split is not publicly disclosed.
Value chain position and customers
Ajinomoto is vertically integrated in umami seasonings: it ferments agricultural feedstock (tapioca, sugar cane molasses, corn) into glutamate and nucleotides, uses part internally for branded seasonings, and sells part to processed food manufacturers. In electronics it sits upstream of substrate makers, supplying the insulating film that those firms laminate into package substrates for chip designers and foundry customers. In pharma it is a service provider to drug developers.
Customer types: households; foodservice operators; processed food manufacturers; retailers (including private-label customers such as a major US premium grocer for frozen foods); pharmaceutical and biotech firms; IC substrate manufacturers; cosmetics formulators; livestock producers.
End-markets: packaged food, foodservice, coffee, sports nutrition, medical foods, biopharmaceutical manufacturing, semiconductor packaging, personal care, animal nutrition.
Strategy
Framework
Strategy is organised around ASV (Ajinomoto Group Creating Shared Value) and the Medium-Term ASV Initiatives 2030 Roadmap published in February 2023. The roadmap replaced rolling three-year plans with long-range targets. The CEO's management slogan is "Think Well, Do Well!", paired with an execution theme the company calls High-Speed with CHANTO. [FY2025 results presentation]
2030 Roadmap targets and progress
| ASV indicator | FY2023 | FY2024 | FY2025 | FY2026 forecast | FY2030 target |
|---|---|---|---|---|---|
| ROE (%) | 11.0 | 9.0 | 17.7 | 15 | 20 |
| ROIC (%) | 8.7 | 6.7 | 11.8 | 11 | 17 |
| Organic sales growth (%) | 1.7 | 3.7 | 3.7 | 9 | 5 |
| EBITDA margin (%) | 15.7 | 16.1 | 17.1 | 17 | 19 |
| Employee engagement score (%) | 76 | 76 | 78 | 84 | 88 |
| Brand value (USD M, Interbrand) | 1,625 | 1,972 | 2,425 | — | — |
Other roadmap commitments: EPS about three times the FY2022 level by FY2030; capital investment of about JPY 750 billion and about JPY 300 billion earmarked for M&A over FY2023 to FY2030; net interest-bearing debt to EBITDA held at 2x or below (company definition); progressive dividend; three-year total return ratio of 50% or more. The FY2030 organic growth target applies to FY2026 to FY2030. [FY2025 results presentation]
Four growth areas
The roadmap identifies Healthcare, Food & Wellness, ICT and Green as growth areas. ICT (ABF and adjacent electronic materials) and Healthcare (CDMO, gene therapy, ADC technology) are where incremental capital is concentrated.
Initiatives announced in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Seven company-wide strategies | May 2026 | Medium- to long-term growth; portfolio; financial and capital; "Speed Up x Scale Up" of execution; sustainability; stakeholder engagement; governance and compliance |
| Company-Wide Growth Strategy Committee | May 2026 | CEO, CHRO, CXO, finance officer and both division heads; monthly; tasked with a post-2030 growth strategy |
| INNOSEED by AJINOMOTO | May 2026 | Innovation programme combining internal cross-functional projects, external partnering, technology-led commercialisation, spin-outs and carve-outs |
| CHRO creation and Corporate Division abolition | Jan to Apr 2026 | Revised personnel and compensation systems to reward results and risk-taking |
| Regional Compliance Committees | FY2026 | New bodies under the Group Compliance Committee in four regional headquarters |
| ABF capacity | 2023 onward; May 2026 | JPY 25 billion expansion programme to 2030, plus Kani City site for post-2030 demand |
| Absorption of Ajinomoto Fine-Techno | Aug 2026 | Merger into parent effective 1 April 2027 to consolidate functional materials talent and organisation |
| Frozen Foods value plan | May 2026 | Raise ROIC by about 3 points by FY2030 through "Deliciousness Technology", operational excellence and further asset efficiency |
| AJICAP ecosystem | Mar to Apr 2026 | CRO and CMO collaborations (NJ Bio; Piramal Pharma Solutions) to widen ADC adoption |
| Head office relocation and asset sale | 2024 to 2026 | Move to leased space; JPY 45.1 billion sale of owned building |
| Capital return | May and Nov 2025 | JPY 100 billion buyback (completed, 27.9 million shares) and JPY 80 billion buyback (to 30 Nov 2026) |
| Data-driven management | FY2025 theme | Redesign of business processes with AI in mind |
Guidance
| FY2026 forecast (JPY Bn) | Initial (7 May 2026) | Revised (6 Aug 2026) |
|---|---|---|
| Sales | 1,723.0 | 1,732.0 |
| Business profit | 197.0 | 202.0 |
| Profit attributable to owners | 120.0 | 123.5 |
| Dividend per share (JPY) | 50 | 50 (unchanged as far as verified) |
Assumptions: JPY 150 per USD; JPY 180 per EUR. The base forecast excludes the Middle East situation; management estimated a potential business profit impact of about JPY 30 billion in May (Dubai crude USD 110, JPY 158), reduced to about JPY 25 billion in August. FY2026 capital investment is planned at about JPY 129.5 billion. [Kessan Tanshin FY2025; Q1 FY2026 materials]
Products & Services
Pricing is not publicly disclosed for any product line unless stated. Launch years are from analyst knowledge of company history and should be confirmed against the company chronicle.
Seasonings and Foods — Sauce & Seasonings
| Product / brand | Description | Target customer | Launch | Notes |
|---|---|---|---|---|
| AJI-NO-MOTO | Monosodium glutamate umami seasoning | Households, foodservice | 1,909 | Founding product; sold in consumer and bulk formats |
| HON-DASHI | Bonito-based granulated Japanese soup stock | Japanese households | 1,970 | Flagship flavour seasoning in Japan |
| Cook Do | Menu-specific Chinese and Asian cooking sauces | Japanese households | 1,978 | Growth driver in FY2025 Japan sales |
| Ajinomoto KK Consommé | Western-style bouillon | Japanese households | 1960s | — |
| Pure Select Mayonnaise | Mayonnaise | Japanese households | 1968 lineage | Competes with Kewpie |
| Ros Dee | Flavour seasoning (pork, chicken) | Thai households | 1,979 | Market leader in Thailand; halal and reduced-salt variants |
| Masako | Flavour seasoning | Indonesian households | 1,989 | — |
| Aji-ngon | Flavour seasoning | Vietnamese households | 2,000 | — |
| Sazón | Flavour seasoning | Brazilian households | 1,988 | Sold in Brazil for more than 30 years |
| Sajiku | Menu-specific seasoning and coating flour | Indonesia | 1990s | — |
| CRISPY FRY | Breading mix | Philippines | 1990s | — |
Seasonings and Foods — Quick Nourishment
| Product / brand | Description | Target customer | Notes |
|---|---|---|---|
| Knorr Cup Soup | Instant soups (brand licensed for Japan) | Japanese households | — |
| YumYum | Instant noodles | Thailand and export | — |
| Birdy | Canned coffee and 3-in-1 powdered drinks | Thailand | — |
| Blendy (CAFÉ LATORY, stick coffee) | Instant and stick coffee | Japan | Operated through Ajinomoto AGF; coffee prices raised in FY2025 to offset bean costs |
| MAXIM | Instant coffee | Japan | — |
| Chotto Zeitakuna Kohiten | Regular coffee | Japan | — |
| Gift sets, office coffee machines, tea servers | Seasonal gifting and workplace beverage supply | Japan B2B and consumers | — |
Seasonings and Foods — Solution & Ingredients
| Product | Description | Target customer |
|---|---|---|
| Bulk AJI-NO-MOTO | Umami seasoning for industrial use | Food processors, foodservice |
| Savory seasonings | Yeast extracts, kokumi and flavour systems | Food processors |
| ACTIVA | Transglutaminase enzyme preparation for texture | Meat, fish and dairy processors |
| Nucleotides | Disodium inosinate and guanylate | Food processors |
| Aspartame and other sweeteners | High-intensity sweeteners for industrial use | Beverage and food manufacturers |
| Delicatessen and bakery products | Prepared foods and frozen dough | Retailers, foodservice |
S&I sales and profit fell in FY2025 because the market for umami seasonings sold to processed food makers was weak. [Kessan Tanshin FY2025]
Frozen Foods
| Product | Description | Markets |
|---|---|---|
| Gyoza / Pot stickers | Flagship pan-fried dumplings; Japanese hane-style and microwaveable variants | Japan, North America, Europe, Brazil |
| THE CHA-HAN, Chicken Fried Rice, Yakitori Chicken with Japanese-Style Fried Rice | Frozen cooked rice | Japan, North America |
| Yakisoba, Ramen | Frozen noodles | North America, Japan |
| THE SHUMAI, Ebi shumai | Steamed dumplings | Japan, North America |
| Yawaraka Wakadori Kara-Age, THE KARAAGE | Fried chicken | Japan |
| Cakes, macarons | Desserts for restaurant and industrial use | Japan, Europe |
| Aete | Nutritionally balanced frozen meals | Japan |
| 2026 US additions | Sweet & Spicy Chili Saucy Pork & Chicken Gyoza; Jumbo Chicken Shumai (May 2026) | United States |
Private-label manufacturing is material in North America (for example chicken fried rice produced for Trader Joe's at the Portland, Oregon plant).
Healthcare and Others
| Product / service | Description | Customer | Notes |
|---|---|---|---|
| Pharmaceutical and food-grade amino acids | High-purity amino acids for infusions, cell culture and nutrition | Pharma, food, biopharma | Sales grew in FY2025 on biopharma and culture media demand |
| Cell culture media | Media and supplements for biologics and regenerative medicine | Biopharma | Supplements co-developed with Forge raise viral vector productivity up to about 2x under company test conditions (Nov 2025) |
| Bio-Pharma Services, small molecule | API and intermediate CDMO, mainly Europe (Belgium) and India | Pharma | Core earnings base |
| AJIPHASE | Liquid-phase synthesis platform for oligonucleotides and peptides | Pharma | Shipment timing drives quarterly volatility |
| AJICAP | Site-specific antibody-drug conjugate (ADC) conjugation technology, licensed and offered as a service | Pharma, biotech | Collaborations with NJ Bio (March 2026) and Piramal Pharma Solutions (April 2026) |
| Forge Biologics | AAV gene therapy and plasmid CDMO, Ohio | Gene therapy developers | Sales about 1.5x prior year in FY2025; EBITDA break-even planned for FY2026 |
| Ajinomoto Build-up Film (ABF) | Film-type interlayer insulating material for semiconductor package substrates | Substrate makers | Servers and networks about 70% of volume in FY2025; business profit margin above 50% |
| PLENSET | One-component epoxy adhesives | Electronics assemblers | — |
| AFTINNOVA Magnetic Film | Magnetic film for inductors embedded in substrates | Electronics | — |
| Activated carbon, release paper | Functional materials | Industrial | — |
| Feed-use amino acids (including AjiPro-L) | Rumen-protected lysine and other feed additives | Dairy and livestock | — |
| amino VITAL | Amino acid sports supplements | Athletes, consumers | — |
| Amisoft, Eldew, Amihope | Amino-acid-based surfactants, oils and powders | Cosmetics formulators | — |
| Medical foods (Cambrooke and others) | Foods for inborn errors of metabolism and clinical nutrition | Patients, clinicians | — |
| Crop services | Biostimulants | Growers | — |
Product Portfolio
| Product / brand | Description | Target customer | Launch | Notes |
|---|---|---|---|---|
AJI-NO-MOTO | Monosodium glutamate umami seasoning | Households, foodservice | 1,909 | Founding product; sold in consumer and bulk formats |
HON-DASHI | Bonito-based granulated Japanese soup stock | Japanese households | 1,970 | Flagship flavour seasoning in Japan |
Cook Do | Menu-specific Chinese and Asian cooking sauces | Japanese households | 1,978 | Growth driver in FY2025 Japan sales |
Ajinomoto KK Consommé | Western-style bouillon | Japanese households | 1960s | — |
Pure Select Mayonnaise | Mayonnaise | Japanese households | 1968 lineage | Competes with Kewpie |
Ros Dee | Flavour seasoning (pork, chicken) | Thai households | 1,979 | Market leader in Thailand; halal and reduced-salt variants |
Masako | Flavour seasoning | Indonesian households | 1,989 | — |
Aji-ngon | Flavour seasoning | Vietnamese households | 2,000 | — |
Sazón | Flavour seasoning | Brazilian households | 1,988 | Sold in Brazil for more than 30 years |
Sajiku | Menu-specific seasoning and coating flour | Indonesia | 1990s | — |
CRISPY FRY | Breading mix | Philippines | 1990s | — |
| Product / brand | Description | Target customer | Notes |
|---|---|---|---|
Knorr Cup Soup | Instant soups (brand licensed for Japan) | Japanese households | — |
YumYum | Instant noodles | Thailand and export | — |
Birdy | Canned coffee and 3-in-1 powdered drinks | Thailand | — |
Blendy (CAFÉ LATORY, stick coffee) | Instant and stick coffee | Japan | Operated through Ajinomoto AGF; coffee prices raised in FY2025 to offset bean costs |
MAXIM | Instant coffee | Japan | — |
Chotto Zeitakuna Kohiten | Regular coffee | Japan | — |
Gift sets, office coffee machines, tea servers | Seasonal gifting and workplace beverage supply | Japan B2B and consumers | — |
| Product | Description | Target customer |
|---|---|---|
Bulk AJI-NO-MOTO | Umami seasoning for industrial use | Food processors, foodservice |
Savory seasonings | Yeast extracts, kokumi and flavour systems | Food processors |
ACTIVA | Transglutaminase enzyme preparation for texture | Meat, fish and dairy processors |
Nucleotides | Disodium inosinate and guanylate | Food processors |
Aspartame and other sweeteners | High-intensity sweeteners for industrial use | Beverage and food manufacturers |
Delicatessen and bakery products | Prepared foods and frozen dough | Retailers, foodservice |
| Product | Description | Markets |
|---|---|---|
Gyoza / Pot stickers | Flagship pan-fried dumplings; Japanese hane-style and microwaveable variants | Japan, North America, Europe, Brazil |
THE CHA-HAN, Chicken Fried Rice, Yakitori Chicken with Japanese-Style Fried Rice | Frozen cooked rice | Japan, North America |
Yakisoba, Ramen | Frozen noodles | North America, Japan |
THE SHUMAI, Ebi shumai | Steamed dumplings | Japan, North America |
Yawaraka Wakadori Kara-Age, THE KARAAGE | Fried chicken | Japan |
Cakes, macarons | Desserts for restaurant and industrial use | Japan, Europe |
Aete | Nutritionally balanced frozen meals | Japan |
2026 US additions | Sweet & Spicy Chili Saucy Pork & Chicken Gyoza; Jumbo Chicken Shumai (May 2026) | United States |
| Product / service | Description | Customer | Notes |
|---|---|---|---|
Pharmaceutical and food-grade amino acids | High-purity amino acids for infusions, cell culture and nutrition | Pharma, food, biopharma | Sales grew in FY2025 on biopharma and culture media demand |
Cell culture media | Media and supplements for biologics and regenerative medicine | Biopharma | Supplements co-developed with Forge raise viral vector productivity up to about 2x under company test conditions (Nov 2025) |
Bio-Pharma Services, small molecule | API and intermediate CDMO, mainly Europe (Belgium) and India | Pharma | Core earnings base |
AJIPHASE | Liquid-phase synthesis platform for oligonucleotides and peptides | Pharma | Shipment timing drives quarterly volatility |
AJICAP | Site-specific antibody-drug conjugate (ADC) conjugation technology, licensed and offered as a service | Pharma, biotech | Collaborations with NJ Bio (March 2026) and Piramal Pharma Solutions (April 2026) |
Forge Biologics | AAV gene therapy and plasmid CDMO, Ohio | Gene therapy developers | Sales about 1.5x prior year in FY2025; EBITDA break-even planned for FY2026 |
Ajinomoto Build-up Film (ABF) | Film-type interlayer insulating material for semiconductor package substrates | Substrate makers | Servers and networks about 70% of volume in FY2025; business profit margin above 50% |
PLENSET | One-component epoxy adhesives | Electronics assemblers | — |
AFTINNOVA Magnetic Film | Magnetic film for inductors embedded in substrates | Electronics | — |
Activated carbon, release paper | Functional materials | Industrial | — |
Feed-use amino acids (including AjiPro-L) | Rumen-protected lysine and other feed additives | Dairy and livestock | — |
amino VITAL | Amino acid sports supplements | Athletes, consumers | — |
Amisoft, Eldew, Amihope | Amino-acid-based surfactants, oils and powders | Cosmetics formulators | — |
Medical foods (Cambrooke and others) | Foods for inborn errors of metabolism and clinical nutrition | Patients, clinicians | — |
Crop services | Biostimulants | Growers | — |
Financial Narrative
Sources: Company IR "Financial Highlights" (IFRS) pages for FY2021 to FY2025; Kessan Tanshin FY2025 (7 May 2026) for full FY2024 and FY2025 statements; FY2025 results presentation for ROIC and EBITDA margin.
Income statement
Notes:
-
Operating profit for FY2021 and FY2022 is from analyst recollection of company releases (JPY 124.6 bn and JPY 148.9 bn). One aggregator shows 126,493 and 150,177 for the same years; the difference likely reflects vendor reclassification. Gross profit for FY2021 to FY2023 is from the same aggregator, which cites the Yuho.
-
EBITDA for FY2024 and FY2025 is business profit plus depreciation and amortization (JPY 86,461 M and JPY 88,914 M). FY2023 is derived from the disclosed 15.7% EBITDA margin.
-
FY2024 dividend was JPY 80 pre-split, shown as 40 post-split.
Margins and growth
Revenue CAGR: 8.3% for FY2021 to FY2025 (four years); 8.1% for FY2020 (JPY 1,071,453 M) to FY2025 (five years). Derived.
Balance sheet
Notes: Short-term debt is short-term borrowings plus current portions of bonds and long-term borrowings. Long-term debt is corporate bonds plus long-term borrowings. "Interest-bearing debt, company definition" is derived from the disclosed ratio of interest-bearing debt to operating cash flow (292.5%, 236.3%, 201.7%) and includes lease liabilities; values are rounded.
Ratios
Notes: ROE, ROA, ROIC and interest coverage are company-disclosed. Other ratios are derived. The cash conversion cycle uses "trade and other" receivables and payables, which overstates both; treat as indicative.
Commentary
Revenue. The 18% jump in FY2022 combined yen depreciation with price increases taken to recover raw material inflation. Growth has since decelerated to low-to-mid single digits. FY2025's 3.5% included roughly one point of currency benefit and a negative perimeter effect from the Althea disposal.
Gross margin. The margin fell 2.5 points in FY2022 as input costs outran pricing, then recovered every year to 37.7% in FY2025, above the FY2021 level. Mix shift toward ABF and overseas price increases (about JPY 11.5 billion in FY2025) drove the recovery. [FY2025 results presentation]
Business profit versus operating profit. The two diverge sharply in FY2024 and FY2025. In FY2024, other operating expenses of JPY 50.3 billion (principally impairment of Ajinomoto Althea's goodwill and fixed assets) cut operating profit to JPY 114.0 billion. In FY2025, other operating income of JPY 48.6 billion (including the JPY 40.6 billion head office gain) lifted operating profit to JPY 199.4 billion. Neither year is representative; business profit is the cleaner trend line.
Net income and ROE. FY2025 ROE of 17.7% is flattered by the property gain. Excluding special factors and Forge, the company presents an adjusted figure. Management guides to about 15% for FY2026 against a 2030 target of about 20%.
Balance sheet. Equity has not grown since FY2023 despite record profit, because JPY 220.7 billion of buybacks across FY2024 and FY2025 were returned to shareholders. Cash fell to JPY 106.7 billion. Leverage remains modest at about 1.2x net debt to EBITDA.
Cash flow. Operating cash flow has more than doubled from FY2022 to a record JPY 239.4 billion, aided in FY2025 by a JPY 55.8 billion increase in payables. Capital expenditure is rising (FY2026 plan about JPY 130 billion) for ABF capacity and food plants.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Sub-segments | Main products |
|---|---|---|
Seasonings and Foods | Sauce & Seasonings; Quick Nourishment; Solution & Ingredients (S&I) | AJI-NO-MOTO, HON-DASHI, Cook Do, consommé, Pure Select mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, CRISPY FRY; Knorr Cup Soup, YumYum noodles, Birdy coffee, Blendy and MAXIM coffee; foodservice seasonings, ACTIVA enzyme, nucleotides, aspartame |
Frozen Foods | Frozen Foods | Gyoza and pot stickers, cooked rice, noodles, shumai, fried chicken, desserts |
Healthcare and Others | Amino Acids for Pharmaceuticals and Foods; Bio-Pharma Services (CDMO); Functional Materials; Others | Amino acids and culture media; contract manufacture of intermediates and APIs; ABF, PLENSET adhesive, AFTINNOVA magnetic film; feed-use amino acids, amino VITAL, Amisoft, medical foods, crop services |
Other | Tie-up and service businesses | — |
Segment sales (JPY Mn)
| Segment sales (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Seasonings and Foods | 847,000 | 896,012 | 936,926 |
Frozen Foods | 281,900 | 289,388 | 290,308 |
Healthcare and Others | 294,500 | 328,397 | 341,504 |
Other | 15,800 | 16,758 | 14,979 |
Total | 1,439,231 | 1,530,556 | 1,583,719 |
Segment business profit (JPY Mn)
| Segment business profit (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Seasonings and Foods | 127,500 | 134,129 | 143,036 |
Frozen Foods | 13,900 | 13,015 | 8,457 |
Healthcare and Others | 36,450 | 45,640 | 66,202 |
Other | — | 6,379 | 6,064 |
Shared companywide expenses | — | -39,862 | -42,597 |
Total business profit | 147,681 | 159,302 | 181,163 |
Segment business profit margin (%)
| Segment business profit margin (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Seasonings and Foods | 15.1 | 15.0 | 15.3 |
Frozen Foods | 4.9 | 4.5 | 2.9 |
Healthcare and Others | 12.4 | 13.9 | 19.4 |
Segment sales growth YoY (%)
| Segment sales growth YoY (%) | FY2024 | FY2025 |
|---|---|---|
Seasonings and Foods | 5.8 | 4.6 |
Frozen Foods | 2.7 | 0.3 |
Healthcare and Others | 11.5 | 4.0 |
Other | 5.9 | -10.6 |
Share of group sales (%)
| Share of group sales (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Seasonings and Foods | 58.9 | 58.5 | 59.2 |
Frozen Foods | 19.6 | 18.9 | 18.3 |
Healthcare and Others | 20.5 | 21.5 | 21.6 |
Other | 1.1 | 1.1 | 0.9 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Seasonings and Foods ROIC (%) | 18.9 | 20.9 | 20.8 |
Seasonings and Foods EBITDA margin (%) | 19.2 | 19.4 | 19.8 |
Frozen Foods ROIC (%) | 5.5 | 4.1 | 3.4 |
Frozen Foods organic growth (%) | 0.6 | -0.9 | 0.4 |
Healthcare and Others ROIC (%) | 6.8 | 2.0 | 12.0 |
Healthcare and Others EBITDA margin (%) | 19.1 | 21.5 | 26.5 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Sales (JPY Mn) | 1,149,370 | 1,359,115 | 1,439,231 | 1,530,556 | 1,583,719 |
Gross profit (JPY Mn) | 425,898 | 470,388 | 511,448 | 550,764 | 597,148 |
Business profit (JPY Mn) | 120,915 | 135,341 | 147,681 | 159,302 | 181,163 |
Operating profit (JPY Mn) | 124,572 | 148,928 | 146,682 | 113,968 | 199,412 |
EBITDA, business profit plus D&A (JPY Mn) | — | — | 225,959 | 245,763 | 270,077 |
Profit before income taxes (JPY Mn) | 122,472 | 140,033 | 142,043 | 108,330 | 196,115 |
Profit for the year (JPY Mn) | 80,228 | 100,170 | 102,032 | 80,773 | 145,060 |
Profit attributable to owners (JPY Mn) | 75,725 | 94,065 | 87,121 | 70,272 | 134,675 |
Basic EPS, split-adjusted (JPY) | 69.71 | 87.99 | 83.72 | 69.77 | 138.36 |
Diluted EPS, split-adjusted (JPY) | — | — | 83.70 | 69.77 | 138.36 |
Dividend per share, split-adjusted (JPY) | 26 | 34 | 37 | 40 | 48 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Sales growth YoY (%) | 7.3 | 18.2 | 5.9 | 6.3 | 3.5 |
Gross margin (%) | 37.1 | 34.6 | 35.5 | 36.0 | 37.7 |
Business profit margin (%) | 10.5 | 10.0 | 10.3 | 10.4 | 11.4 |
Operating margin (%) | 10.8 | 11.0 | 10.2 | 7.4 | 12.6 |
EBITDA margin (%) | — | — | 15.7 | 16.1 | 17.1 |
Net margin, attributable (%) | 6.6 | 6.9 | 6.1 | 4.6 | 8.5 |
Organic sales growth (%) | — | — | 1.7 | 3.7 | 3.7 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 1,457,060 | 1,511,734 | 1,768,371 | 1,721,131 | 1,812,346 |
Cash and cash equivalents (JPY Mn) | 151,454 | 132,777 | 171,537 | 164,776 | 106,693 |
Short-term debt (JPY Mn) | — | — | — | 39,146 | 40,433 |
Long-term debt (JPY Mn) | — | — | — | 416,207 | 380,922 |
Total debt excluding leases (JPY Mn) | — | — | — | 455,353 | 421,355 |
Interest-bearing debt, company definition (JPY Mn) | — | — | 491,600 | 496,000 | 482,800 |
Net debt excluding leases (JPY Mn) | — | — | — | 290,577 | 314,662 |
Total equity (JPY Mn) | 739,744 | 822,968 | 884,448 | 813,273 | 844,275 |
Equity attributable to owners (JPY Mn) | 686,909 | 768,676 | 815,074 | 746,804 | 770,819 |
Goodwill (JPY Mn) | — | — | — | 117,940 | 124,051 |
Intangible assets (JPY Mn) | — | — | — | 92,168 | 92,231 |
Working capital, current assets less current liabilities (JPY Mn) | — | — | — | 316,710 | 255,107 |
Equity ratio (%) | 47.1 | 50.8 | 46.1 | 43.4 | 42.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 145,576 | 117,640 | 168,074 | 209,898 | 239,351 |
Investing cash flow (JPY Mn) | -61,567 | -30,087 | -132,434 | -77,382 | -84,229 |
Financing cash flow (JPY Mn) | -123,055 | -111,061 | -6,753 | -137,684 | -225,603 |
Purchase of PP&E (JPY Mn) | — | — | — | 88,104 | 96,446 |
Purchase of intangibles (JPY Mn) | — | — | — | 6,986 | 8,104 |
Free cash flow, OCF less PP&E and intangibles (JPY Mn) | — | — | — | 114,808 | 134,801 |
OCF plus investing cash flow (JPY Mn) | 84,009 | 87,553 | 35,640 | 132,516 | 155,122 |
Dividends paid to owners (JPY Mn) | — | — | — | 39,136 | 43,159 |
Share buybacks (JPY Mn) | — | — | — | 90,695 | 130,009 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 11.6 | 12.9 | 11.0 | 9.0 | 17.7 |
ROA, business profit to total assets (%) | 8.4 | 9.1 | 9.0 | 9.1 | 10.3 |
ROIC, company definition (%) | 7.9 | 9.9 | 8.7 | 6.7 | 11.8 |
Current ratio (x) | — | — | — | 1.82 | 1.57 |
Debt to equity, excluding leases (x) | — | — | — | 0.56 | 0.50 |
Net debt to EBITDA, excluding leases (x) | — | — | — | 1.18 | 1.17 |
Interest coverage, OCF to interest paid (x) | — | — | 34.8 | 29.5 | 32.7 |
Asset turnover (x) | — | 0.92 | 0.88 | 0.88 | 0.90 |
Cash conversion cycle (days) | — | — | — | 59 | 50 |
Sales by geography (JPY Mn)
| Sales by geography (JPY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Japan | 510,100 | 520,400 | — |
Overseas | 929,100 | 1,010,200 | — |
Total | 1,439,231 | 1,530,556 | 1,583,719 |
Share of group sales (%) (FY2024)
| Share of group sales (%) | FY2024 |
|---|---|
Japan | 34 |
Asia (excluding Japan) | 29 |
Americas | 27 |
EMEA | 10 |
Share of group business profit (%)
| Share of group business profit (%) | FY2024 |
|---|---|
Japan | 38 |
Asia (excluding Japan) | 47 |
Americas | 9 |
EMEA | 6 |
Segment Overview — Seasonings and Foods
| Segment | Japan sales (JPY Bn) | Overseas sales (JPY Bn) | Regional composition disclosed |
|---|---|---|---|
Seasonings and Foods | 291.8 | 604.1 | Japan 32%, Americas 16%, EMEA 5%, Asia approx. 47% (remainder) |
Frozen Foods | 86.7 | 202.6 | Americas 61%, Japan 30%, EMEA 7%, Asia 2% |
Healthcare and Others | Not separately verified | Not separately verified | Japan 40%, Americas 29%, EMEA 27%, Asia 4% |
Market Valuation
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Year-end market capitalization (JPY Bn) | 1,890 | 2,160 | 2,830 | 3,230 | 3,210 |
Point in Time Details
| Point in time | Share price (JPY) | Market cap (JPY trillion) | Source |
|---|---|---|---|
31 Mar 2026 | Approx. 4,400 (derived) | Approx. 4.21 (derived from equity ratio at market price of 232.5%) | Kessan Tanshin FY2025 |
14 Aug 2026 | 5,568 | 5.38 | StockAnalysis |
25 Sep 2026 | 5,051 | 4.77 | Morningstar |
1 Oct 2026 | Approx. 5,200 | Approx. 4.8 to 5.0 | TradingView |
Valuation Multiples
| Multiple | Ajinomoto | Nestlé | Kirin |
|---|---|---|---|
Normalised P/E (x) | 36.1 | 21.9 | 11.7 |
Price / book (x) | 6.2 | 6.6 | 1.7 |
Price / sales (x) | 3.1 | 2.1 | 0.9 |
Price / cash flow (x) | 23.7 | 11.9 | 7.1 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share, split-adjusted (JPY) | 26 | 34 | 37 | 40 | 48 |
Payout ratio (%) | — | — | — | 57.3 | 34.7 |
Total dividends (JPY Mn) | — | — | — | 40,074 | 46,372 |
Buybacks executed (JPY Mn) | — | — | — | 90,695 | 130,009 |
Capital Markets
| Item | Detail |
|---|---|
Credit ratings | S&P long-term rating in the A category and R&I in the AA category per analyst knowledge of the company's rating page. |
Bonds outstanding (31 Mar 2026) | JPY 204.5 bn (JPY 30.0 bn current; JPY 174.5 bn non-current) |
Borrowings (31 Mar 2026) | Short-term JPY 6.4 bn; long-term JPY 210.5 bn including current portion of JPY 4.1 bn |
Maturity profile | JPY 30.0 bn of bonds fall due within FY2026; JPY 25.0 bn was redeemed in FY2025. |
Liquidity | Cash JPY 106.7 bn; unused committed lines JPY 200 bn and USD 100 M; commercial paper programme |
Q1 FY2026 | Financing inflow of JPY 93.6 bn; cash JPY 197.0 bn at 30 June 2026 |
Analyst Conclusions
Management guidance
For FY2026 (year ending 31 March 2027), revised on 6 August 2026: sales JPY 1,732.0 billion (+9.4%), business profit JPY 202.0 billion (+11.5%), profit attributable to owners JPY 123.5 billion (-8.3%, on absence of the property gain). First-quarter business profit of JPY 60.1 billion represents 30% of the full-year target. Segment guidance at the start of the year called for business profit growth of JPY 2.8 billion in Seasonings and Foods, JPY 3.7 billion in Frozen Foods and JPY 13.7 billion in Healthcare and Others; the August revision added about JPY 5.5 billion to Healthcare and Others.
Consensus expectations
Consensus EPS of about JPY 142 for the next financial year sits above company guidance (about JPY 126 to 130), indicating that the market expects further upward revisions. One vendor narrative projects revenue of about JPY 1,933 billion and earnings of about JPY 186 billion by 2029.
Bull case
-
ABF volume, mix and price compound together. Server share of volume rises toward 75% to 85%, layer counts and package sizes grow, and a reported 30% price rise would fall largely to profit at a margin already above 50%.
-
The food core is a reliable funder. Seasonings and Foods earns about 21% ROIC with demonstrated pricing power in both Japan and emerging markets.
-
Self-help is visible. Althea is gone, Forge is nearing break-even, the head office has been monetised, and JPY 280 billion of buybacks have been authorised in eighteen months.
Bear case
-
Valuation leaves little margin. At about 36x normalised earnings the shares price in sustained AI-driven growth; ABF demand corrected sharply in FY2022 to FY2023.
-
Cost shock is not in guidance. The base forecast excludes an estimated JPY 25 billion Middle East-related headwind, equal to about 12% of guided business profit.
-
Capital allocation history in healthcare is mixed. One CDMO acquisition was written down and sold; Frozen Foods has earned below its cost of capital for years without resolution.
Catalysts and monitorables (next 12 months)
| Timing | Item |
|---|---|
| Early November 2026 | H1 FY2026 results; possible second guidance revision; confirmation or otherwise of ABF pricing |
| 30 November 2026 | Expiry of JPY 80 bn buyback; possible renewal |
| February 2027 | Q3 results; raw material pass-through evidence |
| 1 April 2027 | Fine-Techno merger effective |
| May 2027 | FY2026 results; FY2027 guidance; output of the Company-Wide Growth Strategy Committee and any post-2030 framework |
| Ongoing | Forge EBITDA break-even; Frozen Foods ROIC; North American recall remediation; Middle East energy and packaging costs; yen direction; substrate-maker capacity announcements |
Analyst verdict
Ajinomoto has changed its investment identity in three years. In FY2022 it was a defensive Japanese food company with an interesting materials sideline. By the first quarter of FY2026, Functional Materials was growing sales by more than half year on year, the Healthcare and Others segment was contributing most of the group's incremental profit, and the shares carried a beta above 1.5. The underlying quality is real. Business profit has risen every year from JPY 120.9 billion to JPY 181.2 billion, gross margin has recovered to a five-year high, and operating cash flow has doubled. The balance sheet is lightly geared and management under Shigeo Nakamura has been willing to sell assets, exit a failed acquisition and return capital at scale.
The difficulty is price and concentration. Reported ROE of 17.7% includes a property gain that will not repeat, and guided net profit falls this year. The portion of earnings that justifies a multiple nearly double that of global food peers comes from one film sold to a handful of substrate makers serving one capital expenditure cycle. That franchise is exceptionally strong today, and the company is investing sensibly to protect it, but investors are paying for durability that has not yet been tested through an AI downturn. Meanwhile Frozen Foods still destroys value and the cost environment is deteriorating.
On balance this is a high-quality compounder whose fundamentals are improving faster than at any time in a decade, priced close to full value. The evidence supports holding existing positions and adding on weakness tied to cost-driven guidance disappointments, provided ABF pricing and volume indicators remain intact. The principal thesis-breaker would be evidence of substrate inventory build or credible second-source qualification at major customers.
Verification statement: Figures for FY2024, FY2025 and Q1 FY2026 were checked against company disclosures dated 7 May 2026, 19 June 2026 and 6 August 2026. Multi-year highlights for FY2021 to FY2025 were checked against the company's IR financial highlights pages. No figure has been estimated without being labelled as derived.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Independence | Committees | Background |
|---|---|---|---|---|
Kimie Iwata | Chair of the Board | Independent outside | Nomination; Compensation | Outside director since June 2019; chair since June 2021; outside director of Resona Holdings |
George Nakayama | Director | Independent outside | Nomination (chair); Compensation; Audit | Former chairman of Daiichi Sankyo; director since June 2021 |
Mami Indo | Director | Independent outside | Audit (chair); Nomination | Securities and think-tank career; former Securities and Exchange Surveillance Commission; outside director of Mitsui Fudosan |
Yoko Hatta | Director | Independent outside | Compensation; Audit | International tax and accounting; director since June 2022 |
Scott Trevor Davis | Director | Independent outside | Compensation (chair); Nomination | Professor, Rikkyo University; outside director of Bridgestone and SOMPO Holdings; director since June 2023 |
Yukako Wagatsuma | Director | Independent outside | Nomination; Audit | Lawyer (Japan and US); director since June 2024 |
Shigeo Nakamura | Director; Representative Executive Officer, President & CEO | Internal | — | CEO since February 2025 |
Hiroshi Kaho | Director; Representative Executive Officer & Executive Vice President; CHRO | Internal | — | Former President, Ajinomoto Foods North America; EVP and CHRO from April 2026; new to board June 2026 |
Takeshi Saito | Director; Executive Officer & Vice President; Chief Transformation Officer (CXO) | Internal | — | — |
Takumi Matsuzawa | Director | Internal | Audit (standing) | — |
Directors' Remuneration
| Individual | Basic | Short-term incentive | Medium-term stock | Total |
|---|---|---|---|---|
Shigeo Nakamura (CEO) | 57 | 51 | 73 | 183 |
Michael Lish | 124 | 24 | -2 | 146 |
Ichiro Sakakura (including Thai subsidiary pay) | 59 | 31 | 20 | 112 |
Ikuo Kira (including US subsidiary pay) | 72 | 18 | 11 | 103 |
Directors' Remuneration by Group
| Group | Number | Basic | Short-term | Stock | Total |
|---|---|---|---|---|---|
Directors excluding outside | 6 | 277 | 139 | 130 | 547 |
Outside directors | 6 | 131 | 0 | 0 | 131 |
Executive officers | 21 | 589 | 347 | 162 | 1,099 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
3 Feb 2025 | Taro Fujie's term as President ends; Shigeo Nakamura becomes President & CEO | Fujie remains Senior Corporate Advisor (part-time, external activities only) |
20 Jun 2025 | Fujie leaves the board; Nakamura elected director | 147th AGM |
29 Jan 2026 | CHRO post created; Corporate Division abolished | Executive officers in charge of each corporate department take direct responsibility |
1 Apr 2026 | Hiroshi Kaho becomes EVP and CHRO | Moved from Ajinomoto Foods North America |
19 Jun 2026 | Kaho joins board; Shiragami and Sasaki retire | 148th AGM |
Major Shareholders
| Shareholder | Shares | % (excluding treasury) |
|---|---|---|
The Master Trust Bank of Japan (trust account) | 162,328,300 | 16.92 |
Custody Bank of Japan (trust account) | 63,033,900 | 6.57 |
Nippon Life Insurance | 51,413,772 | 5.36 |
Chase Manhattan Bank, London securities lending omnibus | 31,199,320 | 3.25 |
Dai-ichi Life Insurance | 26,199,400 | 2.73 |
State Street Bank and Trust 505001 | 25,177,690 | 2.62 |
Meiji Yasuda Life Insurance | 22,725,010 | 2.37 |
JP Morgan Chase Bank 385642 | 19,033,670 | 1.98 |
JP Morgan Chase Bank 385781 | 13,897,874 | 1.45 |
Government of Norway | 12,721,284 | 1.33 |
Competitive Landscape
Competitors by Segment
| Business | Named competitors |
|---|---|
Umami and flavour seasonings (consumer) | Nestlé (Maggi), Unilever (Knorr outside Japan), CJ CheilJedang, Daesang, Kikkoman, Kewpie, McCormick, regional brands |
MSG and nucleotides (B2B) | Fufeng Group, Meihua Holdings, CJ CheilJedang, Daesang |
Coffee (Japan) | Nestlé Japan, UCC, Key Coffee |
Frozen foods | Nichirei, Maruha Nichiro, Nissui, TableMark (Japan Tobacco), CJ CheilJedang (Bibigo, Schwan's), Conagra, Nestlé |
Amino acids | Evonik, Kyowa Hakko Bio (Kirin), CJ CheilJedang |
CDMO | Lonza, Samsung Biologics, WuXi group, Catalent, Thermo Fisher (Patheon), Nitto Denko Avecia and Agilent (oligonucleotides) |
Build-up film | Sekisui Chemical, Taiyo Holdings and emerging Taiwanese and Chinese suppliers |
Peer Comparison FY2025
| Company | Revenue | Revenue growth | Operating / business margin | R&D intensity |
|---|---|---|---|---|
Ajinomoto (FY2025) | JPY 1,584 bn | 3.5% | 11.4% (business profit) | 2.0% |
Nestlé (2024) | Approx. CHF 91 bn | Approx. 2% organic | Approx. 17% | Approx. 1.9% |
Kikkoman (FY2024) | Approx. JPY 709 bn | Approx. 7% | Approx. 10 to 11% | Under 1% |
Nichirei (FY2024) | Approx. JPY 702 bn | Approx. 3% | Approx. 5 to 6% | Under 1% |
CJ CheilJedang ex-logistics (2024) | Approx. KRW 18 trillion | Flat | Approx. 5 to 6% | Approx. 1% |
